Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock
Beyond The Numbers: 11 Analysts Discuss Biomarin Pharmaceutical Stock
數字之外：11位分析師討論拜瑪林製藥股票
The analysis...Providing a diverse range of perspectives from bullish to bearish, 11 analysts have published ratings on Biomarin Pharmaceutical (NASDAQ:BMRN) in the last three months.
在過去三個月裏，11名分析師對拜瑪林製藥（納斯達克代碼：BMRN）給出了看好到看淡的多樣觀點。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他們最近評級的精簡視圖，顯示了過去30天的不同情緒，並將其與前幾個月進行比較。
Analysts have set 12-month price targets for Biomarin Pharmaceutical, revealing an average target of $107.0, a high estimate of $120.00, and a low estimate of $86.00. This upward trend is evident, with the current average reflecting a 1.9% increase from the previous average price target of $105.00.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 2.07%, the company may need to address challenges in generating satisfactory returns for shareholders.
Understanding Analyst Ratings: A Comprehensive Breakdown
分析師評級：全面解析
登入免費觀看全文
登入/註冊